{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:51:01Z","timestamp":1780411861662,"version":"3.54.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.intimp.2015.04.023","type":"journal-article","created":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T02:24:09Z","timestamp":1429583049000},"page":"209-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Biological drugs in ANCA-associated vasculitis"],"prefix":"10.1016","volume":"27","author":[{"given":"Pamela M.K.","family":"Lutalo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"D'Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.intimp.2015.04.023_bb0005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrrheum.2014.103","article-title":"Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease","volume":"10","author":"Jennette","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2015.04.023_bb0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e26","article-title":"Diagnosis and management of ANCA associated vasculitis","volume":"344","author":"Berden","year":"2012","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.intimp.2015.04.023_bb0015","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","article-title":"Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy","volume":"44","author":"Specks","year":"2001","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.intimp.2015.04.023_bb0020","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","article-title":"Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"Keogh","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.intimp.2015.04.023_bb0025","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","article-title":"Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial","volume":"173","author":"Keogh","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"7","key":"10.1016\/j.intimp.2015.04.023_bb0030","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/art.24637","article-title":"A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"60","author":"Jones","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.intimp.2015.04.023_bb0035","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/rheumatology\/kel098","article-title":"Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab","volume":"45","author":"Stasi","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.intimp.2015.04.023_bb0040","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2796.2005.01494.x","article-title":"Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab","volume":"257","author":"Eriksson","year":"2005","journal-title":"J. Intern. Med."},{"issue":"9","key":"10.1016\/j.intimp.2015.04.023_bb0045","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.intimp.2015.04.023_bb0050","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.intimp.2015.04.023_bb0055","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.intimp.2015.04.023_bb0060","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2015.04.023_bb0065","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/ket445","article-title":"BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis","author":"Ntatsaki","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.intimp.2015.04.023_bb0070","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.lpm.2013.08.003","article-title":"Rituximab: recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides","volume":"42","author":"Charles","year":"2013","journal-title":"Presse Med."},{"issue":"11","key":"10.1016\/j.intimp.2015.04.023_bb0075","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1002\/art.34584","article-title":"Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center","volume":"64","author":"Cartin-Ceba","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.intimp.2015.04.023_bb0080","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.intimp.2015.04.023_bb0085","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/rheumatology\/ket381","article-title":"Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients","volume":"53","author":"Charles","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"19","key":"10.1016\/j.intimp.2015.04.023_bb0090","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.intimp.2015.04.023_bb0095","doi-asserted-by":"crossref","first-page":"R133","DOI":"10.1186\/ar4313","article-title":"Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss syndrome)","volume":"15","author":"Thiel","year":"2013","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2015.04.023_bb0100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/ard.2005.042937","article-title":"Rituximab in Churg\u2013Strauss syndrome","volume":"65","author":"Koukoulaki","year":"2006","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.intimp.2015.04.023_bb0105","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/rheumatology\/ken175","article-title":"Rituximab is effective in the treatment of refractory Churg\u2013Strauss syndrome and is associated with diminished T-cell interleukin-5 production","volume":"47","author":"Pepper","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.intimp.2015.04.023_bb0110","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/ard.2005.047308","article-title":"Successful use of rituximab in a patient with recalcitrant Churg\u2013Strauss syndrome","volume":"65","author":"Kaushik","year":"2006","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2015.04.023_bb0115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12016-007-8019-0","article-title":"Rituximab as a therapeutic tool in severe mixed cryoglobulinemia","volume":"34","author":"Roccatello","year":"2008","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2015.04.023_bb0120","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/ard.2009.109850","article-title":"Successful use of rituximab in a patient with Churg\u2013Strauss syndrome and refractory central nervous system involvement","volume":"69","author":"Saech","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2015.04.023_bb0125","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00296-009-1146-6","article-title":"Churg\u2013Strauss syndrome successfully treated with rituximab","volume":"31","author":"Donvik","year":"2011","journal-title":"Rheumatol. Int."},{"issue":"9","key":"10.1016\/j.intimp.2015.04.023_bb0130","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1093\/ndt\/gfq852","article-title":"Rituximab for the treatment of Churg\u2013Strauss syndrome with renal involvement","volume":"26","author":"Cartin-Ceba","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"issue":"2","key":"10.1016\/j.intimp.2015.04.023_bb0135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2174\/1871528113666140224103712","article-title":"The risk of progressive multifocal leukoencephalopathy under biological agents used in the treatment of chronic inflammatory diseases","volume":"13","author":"Toussirot","year":"2014","journal-title":"Inflamm. Allergy Drug Targets"},{"issue":"4","key":"10.1016\/j.intimp.2015.04.023_bb0140","doi-asserted-by":"crossref","first-page":"c339","DOI":"10.1159\/000323393","article-title":"Serum levels of BAFF and APRIL in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis: association with disease activity","volume":"118","author":"Nagai","year":"2011","journal-title":"Nephron Clin. Pract."},{"issue":"9","key":"10.1016\/j.intimp.2015.04.023_bb0145","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s10067-010-1526-z","article-title":"B-lymphocyte activating factor levels are increased in patients with Wegener's granulomatosis and inversely correlated with ANCA titer","volume":"29","author":"Bader","year":"2010","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2015.04.023_bb0150","first-page":"62","article-title":"Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV)","volume":"28","author":"Schneeweis","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.intimp.2015.04.023_bb0155","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaci.2009.10.014","article-title":"Sustained response to mepolizumab in refractory Churg\u2013Strauss syndrome","volume":"125","author":"Kahn","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2015.04.023_bb0160","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","article-title":"Mepolizumab as a steroid-sparing treatment option in patients with Churg\u2013Strauss syndrome","volume":"125","author":"Kim","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2015.04.023_bb0165","first-page":"S62","article-title":"Extended follow-up after stopping mepolizumab in relapsing\/refractory Churg\u2013Strauss syndrome","volume":"30","author":"Herrmann","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.intimp.2015.04.023_bb0170","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","article-title":"Targeting interleukin-5 in refractory and relapsing Churg\u2013Strauss syndrome","volume":"155","author":"Moosig","year":"2011","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.intimp.2015.04.023_bb0175","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaci.2008.05.024","article-title":"Omalizumab and Churg\u2013Strauss syndrome","volume":"122","author":"Giavina-Bianchi","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2015.04.023_bb0180","doi-asserted-by":"crossref","first-page":"E78","DOI":"10.1002\/ppul.22884","article-title":"Successful management of Churg\u2013Strauss syndrome using omalizumab as adjuvant immunomodulatory therapy: first documented pediatric case","volume":"49","author":"Iglesias","year":"2014","journal-title":"Pediatr. Pulmonol."},{"issue":"8","key":"10.1016\/j.intimp.2015.04.023_bb0185","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/thx.2006.076513","article-title":"Apparent response to anti-IgE therapy in two patients with refractory \u201cforme fruste\u201d of Churg\u2013Strauss syndrome","volume":"63","author":"Pabst","year":"2008","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.intimp.2015.04.023_bb0190","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0197-2456(02)00209-X","article-title":"Design of the Wegener's Granulomatosis Etanercept Trial (WGET)","volume":"23","year":"2002","journal-title":"Control. Clin. Trials"},{"issue":"5","key":"10.1016\/j.intimp.2015.04.023_bb0195","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.21869","article-title":"Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial","volume":"54","author":"Stone","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.intimp.2015.04.023_bb0200","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1002\/art.30394","article-title":"Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort","volume":"63","author":"Silva","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.intimp.2015.04.023_bb0205","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/ard.61.6.559","article-title":"Safety and efficacy of TNFalpha blockade in relapsing vasculitis","volume":"61","author":"Booth","year":"2002","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2015.04.023_bb0210","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.ASN.0000114554.67106.28","article-title":"Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis","volume":"15","author":"Booth","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.intimp.2015.04.023_bb0215","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/rheumatology\/41.11.1303","article-title":"Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis","volume":"41","author":"Lamprecht","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.intimp.2015.04.023_bb0220","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/41.10.1126","article-title":"Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients","volume":"41","author":"Bartolucci","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl. 4","key":"10.1016\/j.intimp.2015.04.023_bb0225","doi-asserted-by":"crossref","first-page":"iv31","DOI":"10.1136\/ard.2005.042416","article-title":"Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis","volume":"64","author":"Mukhtyar","year":"2005","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2015.04.023_bb0230","doi-asserted-by":"crossref","first-page":"c89","DOI":"10.1159\/000319655","article-title":"Addition of infliximab to standard therapy for ANCA-associated vasculitis","volume":"117","author":"Morgan","year":"2011","journal-title":"Nephron Clin. Pract."},{"key":"10.1016\/j.intimp.2015.04.023_bb0235","first-page":"S63","article-title":"Infliximab or rituximab for refractory Wegener's granulomatosis: long-term followup. A prospective randomised multicentre study on 17 patients","volume":"29","author":"de Menthon","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"issue":"10","key":"10.1016\/j.intimp.2015.04.023_bb0240","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1093\/ndt\/gfq187","article-title":"Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement","volume":"25","author":"Laurino","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"issue":"9","key":"10.1016\/j.intimp.2015.04.023_bb0245","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/ard.2007.081661","article-title":"Long-term follow-up of relapsing\/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)","volume":"67","author":"Walsh","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.intimp.2015.04.023_bb0250","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/annrheumdis-2013-204164","article-title":"An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's)","volume":"73","author":"Langford","year":"2014","journal-title":"Ann. Rheum. Dis."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576915001873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576915001873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T19:46:43Z","timestamp":1747943203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576915001873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1567576915001873"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2015.04.023","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biological drugs in ANCA-associated vasculitis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2015.04.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}